Different tumors in bone each give rise to a distinct pattern of skeletal destruction, bone cancer-related pain behaviors and neurochemical changes in the central nervous system

被引:99
作者
Sabino, MAC
Luger, NM
Mach, DB
Rogers, SD
Schwei, MJ
Mantyh, PW
机构
[1] Univ Minnesota, Neurosyst Ctr, Minneapolis, MN USA
[2] Univ Minnesota, Dept Prevent Sci, Minneapolis, MN USA
[3] Univ Minnesota, Dept Psychiat, Minneapolis, MN USA
[4] Univ Minnesota, Dept Neurosci, Minneapolis, MN USA
[5] Univ Minnesota, Ctr Canc, Minneapolis, MN USA
[6] VA Med Ctr, Minneapolis, MN USA
关键词
nociception; heterogeneity; sensitization; tumor; osteolysis; metastasis;
D O I
10.1002/ijc.10999
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pain is the most common presenting symptom in patients with bone cancer and bone cancer pain can be both debilitating and difficult to control fully. To begin to understand the mechanisms involved in the generation and maintenance of bone cancer pain, we implanted 3 well-described murine tumor cell lines, 2472 sarcoma, B16 melanoma and C26 colon adenocarcinoma into the femur of immunocompromised C3H-SCID mice. Although each of the tumor cell lines proliferated and completely filled the intramedullary space of the femur within 3 weeks, the location and extent of bone destruction, the type and severity of the pain behaviors and the neurochemical reorganization of the spinal cord was unique to each tumor cell line injected. These data suggest that bone cancer pain is not caused by a single factor such as increased pressure induced by intramedullary tumor growth, but rather that multiple factors are involved in generating and maintaining bone cancer pain. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:550 / 558
页数:9
相关论文
共 84 条
[1]   Differential contribution of the two phases of the formalin test to the pattern of c-fos expression in the rat spinal cord: Studies with remifentanil and lidocaine [J].
Abbadie, C ;
Taylor, BK ;
Peterson, MA ;
Basbaum, AI .
PAIN, 1997, 69 (1-2) :101-110
[2]  
Abbadie C, 1997, J NEUROSCI, V17, P8049
[3]  
Adami S, 1997, CANCER, V80, P1674, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1674::AID-CNCR18>3.3.CO
[4]  
2-D
[5]  
ARGUELLO F, 1988, CANCER RES, V48, P6876
[6]  
BASBAUM A, 1994, APS J, V3, P49
[7]   SUBSTANCE-P-IMMUNOREACTIVE AND CGRP-IMMUNOREACTIVE NERVES IN BONE [J].
BJURHOLM, A ;
KREICBERGS, A ;
BRODIN, E ;
SCHULTZBERG, M .
PEPTIDES, 1988, 9 (01) :165-171
[8]   NEUROPEPTIDE Y-IMMUNOREACTIVE, TYROSINE HYDROXYLASE-IMMUNOREACTIVE AND VASOACTIVE INTESTINAL POLYPEPTIDE-IMMUNOREACTIVE NERVES IN BONE AND SURROUNDING TISSUES [J].
BJURHOLM, A ;
KREICBERGS, A ;
TERENIUS, L ;
GOLDSTEIN, M ;
SCHULTZBERG, M .
JOURNAL OF THE AUTONOMIC NERVOUS SYSTEM, 1988, 25 (2-3) :119-125
[9]  
Cahlin C, 2000, CANCER RES, V60, P1742
[10]   Functional interactions between tumor and peripheral nerve: Changes in excitability and morphology of primary afferent fibers in a murine model of cancer pain [J].
Cain, DM ;
Wacnik, PW ;
Turner, M ;
Wendelschafer-Crabb, G ;
Kennedy, WR ;
Wilcox, GL ;
Simone, DA .
JOURNAL OF NEUROSCIENCE, 2001, 21 (23) :9367-9376